ATE232102T1 - Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose - Google Patents
Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthroseInfo
- Publication number
- ATE232102T1 ATE232102T1 AT97906339T AT97906339T ATE232102T1 AT E232102 T1 ATE232102 T1 AT E232102T1 AT 97906339 T AT97906339 T AT 97906339T AT 97906339 T AT97906339 T AT 97906339T AT E232102 T1 ATE232102 T1 AT E232102T1
- Authority
- AT
- Austria
- Prior art keywords
- arthrosis
- syndrome
- treatment
- rheumatoid
- diseases
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 229960003980 galantamine Drugs 0.000 abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000029147 Collagen-vascular disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 abstract 1
- 208000028387 Felty syndrome Diseases 0.000 abstract 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 abstract 1
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 206010065159 Polychondritis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010014665 endocarditis Diseases 0.000 abstract 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010033675 panniculitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005987 polymyositis Diseases 0.000 abstract 1
- 208000002574 reactive arthritis Diseases 0.000 abstract 1
- 208000009169 relapsing polychondritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS4325 | 1996-02-19 | ||
| GBGB9606736.8A GB9606736D0 (en) | 1996-02-19 | 1996-03-29 | Therapeutic method |
| PCT/IS1997/000001 WO1997029750A1 (en) | 1996-02-19 | 1997-02-19 | Treatment of arthritis disorders, rheumatoid arthritis and manifestations associated with rheumatoid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE232102T1 true ATE232102T1 (de) | 2003-02-15 |
Family
ID=36764777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97906339T ATE232102T1 (de) | 1996-02-19 | 1997-02-19 | Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6358941B1 (de) |
| EP (1) | EP0918523B1 (de) |
| AT (1) | ATE232102T1 (de) |
| AU (1) | AU2105997A (de) |
| CA (1) | CA2251114C (de) |
| DE (1) | DE69718915T2 (de) |
| DK (1) | DK0918523T3 (de) |
| ES (1) | ES2192667T3 (de) |
| GB (1) | GB9606736D0 (de) |
| WO (1) | WO1997029750A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8742198A (en) * | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| US20030224071A1 (en) * | 1999-08-20 | 2003-12-04 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| WO2002094320A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
| WO2002094321A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US20050048543A1 (en) * | 2003-07-11 | 2005-03-03 | Jeroen Aerssens | CHRNA2 genetic markers associated with galantamine response |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| WO2005042762A2 (en) * | 2003-10-28 | 2005-05-12 | Genaissance Pharmaceuticals, Inc. | Lrpap1 genetic markers associated with galantamine response |
| US7250258B2 (en) * | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
| WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| ES2524309T3 (es) * | 2004-04-20 | 2014-12-05 | Sphingotec Gmbh | Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico médico |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| CN101044200A (zh) * | 2004-09-24 | 2007-09-26 | 巴尔的摩马里兰大学 | 治疗有机磷中毒的方法 |
| US9186345B2 (en) | 2004-10-12 | 2015-11-17 | Hakon Hakonarson | Method of treating skin diseases |
| US20060264455A1 (en) | 2005-05-23 | 2006-11-23 | Schachter Steven C | Use of huperzine for disorders |
| CN101190330A (zh) * | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| FR2912841B1 (fr) * | 2007-02-15 | 2009-05-22 | Soitec Silicon On Insulator | Procede de polissage d'heterostructures |
| US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| US20110224245A1 (en) * | 2008-09-04 | 2011-09-15 | President And Fellows Of Harvard College | Treatment Of Neurological Disorders Using Huperzine |
| CA2894860C (en) | 2008-11-19 | 2018-11-06 | Gerhard Koenig | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| US20120129838A1 (en) * | 2009-04-24 | 2012-05-24 | The Industry & Academic Cooperation In Chungnam National University | Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| US20110212928A1 (en) | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX357676B (es) | 2010-05-17 | 2018-07-18 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| EP2640378A4 (de) * | 2010-11-18 | 2014-05-21 | Envivo Pharmaceuticals Inc | Behandlung von entzündungen mit bestimmten alpha-7-nikotinsäurerezeptoragonisten in kombination mit acetylcholinesterasehemmern |
| EP3666272A1 (de) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Verwendung von encenicline bei der behandlung von kognitiver behinderung, alzheimer-krankheit, speicherdefizit |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2016140867A1 (en) | 2015-03-02 | 2016-09-09 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| WO2018165460A1 (en) | 2017-03-09 | 2018-09-13 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| CN109200051A (zh) * | 2017-07-03 | 2019-01-15 | 南京和博生物医药有限公司 | 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途 |
| WO2020132171A1 (en) | 2018-12-20 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods for imaging and treatment of somatostatin-receptor positive tumors |
| WO2023070351A1 (zh) * | 2021-10-27 | 2023-05-04 | 香港理工大学 | 通过抑制乙酰胆碱酯酶来预防和治疗骨关节疾病 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US661509A (en) * | 1900-09-04 | 1900-11-13 | John S Fogg | Traveler's hat-conformer. |
| US5360811A (en) * | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
| EP0584185B1 (de) | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
-
1996
- 1996-03-29 GB GBGB9606736.8A patent/GB9606736D0/en active Pending
-
1997
- 1997-02-19 EP EP97906339A patent/EP0918523B1/de not_active Expired - Lifetime
- 1997-02-19 CA CA002251114A patent/CA2251114C/en not_active Expired - Fee Related
- 1997-02-19 WO PCT/IS1997/000001 patent/WO1997029750A1/en not_active Ceased
- 1997-02-19 AU AU21059/97A patent/AU2105997A/en not_active Abandoned
- 1997-02-19 DK DK97906339T patent/DK0918523T3/da active
- 1997-02-19 ES ES97906339T patent/ES2192667T3/es not_active Expired - Lifetime
- 1997-02-19 US US09/125,306 patent/US6358941B1/en not_active Expired - Fee Related
- 1997-02-19 AT AT97906339T patent/ATE232102T1/de not_active IP Right Cessation
- 1997-02-19 DE DE69718915T patent/DE69718915T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2251114C (en) | 2007-10-02 |
| DE69718915T2 (de) | 2003-12-11 |
| DK0918523T3 (da) | 2003-05-26 |
| CA2251114A1 (en) | 1997-08-21 |
| EP0918523A1 (de) | 1999-06-02 |
| HK1020535A1 (en) | 2000-05-12 |
| DE69718915D1 (de) | 2003-03-13 |
| ES2192667T3 (es) | 2003-10-16 |
| GB9606736D0 (en) | 1996-06-05 |
| US6358941B1 (en) | 2002-03-19 |
| WO1997029750A1 (en) | 1997-08-21 |
| EP0918523B1 (de) | 2003-02-05 |
| AU2105997A (en) | 1997-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69718915D1 (de) | Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose | |
| BG60698B2 (en) | Pharmaceutical ACCEPTABLE SALTS | |
| MD809C2 (ro) | (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii | |
| BG103190A (en) | Substituted pyrimidine derivatives and their pharmaceutical application | |
| TR200001982T2 (tr) | Farmasötik vurulu salınımlı oral dozaj şekli. | |
| UA41297C2 (uk) | Похідні індолу, фармацевтична композиція і спосіб лікування | |
| DK0869808T3 (da) | Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation | |
| EA200100872A1 (ru) | Композиция валдекоксиба | |
| DE3583008D1 (de) | Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren. | |
| IL112664A0 (en) | 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
| DE69520364D1 (de) | Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme | |
| FI925342A0 (fi) | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi | |
| DE69427704D1 (de) | Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane | |
| DK0794794T3 (da) | Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler | |
| JP2002523370A5 (de) | ||
| ES2173858T3 (es) | Analogos de huperzina a. | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| GR3019782T3 (en) | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents | |
| DK0539479T3 (da) | Heterocykliske forbindelser | |
| ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
| NZ236800A (en) | Di- and tetra-fluoro analogs of squalene epoxidase, preparation and pharmaceutical compositions thereof | |
| PT1007040E (pt) | Utilizacao de fanquinona no tratamento da doenca de alzheimer | |
| MD940152A (ro) | Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV) | |
| AU6415994A (en) | Substituted caprolactams and derivatives thereof useful for treatment of hiv disease | |
| BG103512A (en) | Substituted pyramidine compounds and their application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |